Recent policy developments show Chinese government’s efforts in encouraging pharmaceutical innovation, improving the drug review and approval, and promoting the development of healthcare professionals. Recent noteworthy policy items include:

  • CFDA and MOST jointly released Guiding Opinions on Strengthening and Promoting Technological Innovation in the Food and Drug Sector
  • The China Fundamental Law on Healthcare and Health Promotion (draft) was released
  • 2018 National Health and Family Planning Conference was Held in Beijing
  • CFDA released Technical Guideline on Innovative Drug Phase I Clinical Trial Application
  • CDE released the 26th list of drugs to be included in priority review
  • State Council released Opinions on Training and Motivation of General Practitioners (GP)

The latest issue in English is downloaded Here.